SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron (MU) is trending following an "impressive" quarterly report that included results and guidance exceeding consensus estimates, with analysts subsequently raising price targets. The community is closely watching the stock's price action, debating whether the positive news was already priced in, while also considering the broader AI market and potential overbought conditions. Some traders are expressing frustration with perceived market manipulation and highlighting Micron's growth potential.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure is trending due to positive three-year data on its Huntington's disease drug, AMT-130, exceeding expectations and potentially derisking accelerated FDA approval. Community discussions revolve around the halted stock, potential gap up, and possible links to CLPT, with some expressing concerns about a sharp sell-off. There is also active discussion about potential FDA approval.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to its recent partnership with Red Lobster to implement AI-powered phone ordering across all locations, sparking excitement about potential future deals with larger chains like McDonald's. The community is also focused on the high short interest, anticipating a potential short squeeze, with some highlighting the broader implications of AI adoption across various industries. Bullish sentiment is fueled by the company's growth potential and innovative technology in the voice AI space.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors digest a Wells Fargo upgrade citing expected AWS sales acceleration and a hardware event on September 30th, though some community members express frustration with the stock's YTD performance compared to its peers. Discussions also include the FTC trial regarding Prime enrollments and closures of Amazon Fresh stores in the UK. Some traders are anticipating a potential dip while others are loading up for a Q4 rally.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as news circulates about the company's AI advancements and partnerships, including a collaboration with Nvidia on physical AI and plans to increase AI spending. The community is buzzing with bullish sentiment, viewing BABA as undervalued and drawing comparisons to other tech giants like Amazon and Nvidia. Some traders note China's push for AI self-sufficiency and believe the stock could see substantial growth despite geopolitical concerns.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is seeing active discussion around a recent pullback after a significant run, with community members debating whether it's a buying opportunity or a sign of further decline. The conversation also highlights the influence of board member actions and prominent investors, with some suggesting their moves are impacting the stock's volatility. Community members are weighing the potential impact of upcoming housing data and the company's long-term prospects amid the recent price swings.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss potential catalysts, including government investment and regulatory approvals, that could drive significant growth. The community is highlighting the company's progress in deep-sea mining and its potential role in securing critical mineral supplies. Bullish sentiment is building, with some anticipating multi-bagger returns upon full production.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending due to increased volume and community speculation about potential catalysts, including a possible buyout, upcoming presentations, and the Delaware court case. Community members are discussing insider buying, institutional ownership, and the potential impact of warrants expiring in January 2026. Some are expressing frustration with management and debating whether the stock is undervalued or a value trap.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

Enthusiasm for FIRECOIN.X is building, with many community members signaling they are buying in, anticipating a surge. The coin, associated with the Solana ecosystem, is being actively discussed in the context of potential 'moon flights' and 'fire gains'. Some users are also inquiring about which platforms the crypto can be purchased on.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro ($CLPT) is trending as the community discusses its potential link to gene therapy companies like $QURE and recent FDA approvals in the neuro space, sparking interest in its role in delivering these therapies to the brain. Community members are also pointing to a recently published article and increased chatter from financial influencers as potential catalysts. Bullish sentiment is building due to strong technicals and the expectation of continued growth within the neuro indications sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental drug AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease.Shares of the company rose 3% in the pre-market session at the time of writing.&nbsp;Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">directly on Stocktwits.</a>

Global stock market chart and trading board - stock photo

uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial 

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

Equity

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 


Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Should You Invest in the VanEck Biotech ETF (BBH)?

ASL Strategic Value Fund is calling for shareholders of Avadel Pharmaceuticals to vote out the company’s entire board of directors.According to a letter viewed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/avadel-shareholder-seeks-ousting-drugmakers-entire-board-fa071ead">The Wall Street Journal</a>, ASL alleges that Avadel mishandled the launch of its key drug, Lumryz, resulting in the company missing out on hundreds of millions of dollars in potential revenue.&nbsp;The investment firm reportedly plans to vote its $15 million stake against all of Avadel’s director nominees at the company’s annual meeting scheduled for late July.The company has been involved in litigation with its main competitor in narcolepsy, Jazz Pharmaceuticals, over patent disputes.In the letter, ASL called on Avadel to issue contingent-value rights (CVRs) to shareholders, which are future payouts tied to possible legal settlements or damages.&nbsp;One of Avadel’s ongoing cases seeks damages in excess of $1 billion.ASL further reiterates its previous demand, first made in February, that Avadel hire an investment bank to explore strategic alternatives, including a potential sale of the company.In response, a spokesperson for Avadel said the board proactively engages with shareholders and that its directors have made personal investments in the company.&nbsp;The company spokesperson further noted that the company continues to focus on “unlocking the full value of Lumryz.”In May, Avadel reported better-than-expected first-quarter sales and raised full-year revenue guidance due to improving demand for Lumryz.The pressure on Avadel comes amid weak performance across the biopharma sector.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The SPDR S&amp;P Biotech ETF</a> is down 9.3% over the past year, while the&nbsp;<a href="https://stocktwits.com/symbol/SPX">S&amp;P 500</a> has gained 5.2%.<a href="https://stocktwits.com/symbol/AVDL">Avadel</a> is a $900 million market cap stock that has seen its&nbsp;stock price rise by 16.4% over the past year.&nbsp;On Stocktwits, retail sentiment for Avadel was ‘neutral’ amid ‘low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One of Avadel’s ongoing cases seeks damages in excess of $1 billion. Representative image via Getty Images

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according to a WSJ report.

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee meeting regarding approval for its Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD) associated cardiomyopathy.Capricor shares were trading 19% higher at the time of writing.The FDA indicated that an advisory committee meeting is not required at this time, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/318/capricor-therapeutics-provides-regulatory-update-on">said</a>, while adding that its application for Deramiocel approval remains under priority review.The company said in May that the FDA is considering an advisory committee meeting, dragging down investor optimism for a possible approval.The agency is expected to decide on the approval of the drug by Aug. 31. &nbsp;Company CEO Linda Marbán said that all regulatory milestones to date have proceeded as expected, and no major issues were noted at the mid-cycle review of the application.An in-person late-cycle meeting is now scheduled for mid-July.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_58_45_PM_png_3f23c3492d.webp" alt="CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the drug getting approved early following the company’s update.<stembedurl>https://stocktwits.com/Drichman7/message/618833665</stembedurl>However, Roth Capital analyst Boobalan Pachaiyappan told investors in a research note that the FDA's intention not to require a meeting "at this time" for Deramiocel “may not necessarily be positive news.”The analyst believes a promissory advisory committee meeting would be positive, as a potential positive panel vote would put pressure on the new FDA leadership to approve deramiocel in its current form.The firm reiterates a ‘Buy’ rating and $31 price target on Capricor shares.H.C. Wainright, however, opined that even in bear case scenarios with the FDA, late-stage trial data readouts are "waiting in the wings" to further strengthen Deramiocel's overall clinical and regulatory package. The analyst believes Deramiocel's first-in-class therapeutic profile, in tandem with strong manufacturing support, will get the therapy over the finish line on expected timelines, as per TheFly.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 34% this year but up by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-presses-congress-to-pass-tax-bill-and-get-the-deal-done-this-week-after-iran-israel-ceasefire/chm4iPpRR3L">Trump Presses Congress To Pass Tax Bill And ‘Get The Deal Done’ This Week After Iran-Israel Ceasefire</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy have been placed on administrative leave.Stat News on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/06/18/top-gene-therapy-regulator-forced-out-at-fda/">reported</a>, citing a recording of a meeting, that Verdun and her deputy Rachael Anatol were escorted out of the agency, sending CAPR shares down on Friday morning. Verdun was the FDA's key overseer of Capricor's application for approval of its Deramiocel drug.Capricor on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/317/capricor-therapeutics-announces-positive-4-year-data-from">announced</a> positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Last month, Capricor announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is now planned for mid-July.Capricor on Friday said that after four years of continuous treatment, Deramiocel-treated patients showed preservation of cardiac function, including Left Ventricular Ejection Fraction, which is a measurement of how well the left ventricle, the heart's main pumping chamber, is working.Treatment also continued to slow the progression of skeletal muscle disease, the company said, while adding that the findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time.CEO Linda Marbán said that the company is moving toward potential approval of the therapy, with several key regulatory steps now completed.“Our continued dialogue with the FDA remains on track with no evidence of any delays,” she said.On Stocktwits, retail sentiment around Capricor jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_10_35_01_AM_png_6034c09f71.webp" alt="CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that, although things don't look good, the new 4-year data from the study could ‘change things’ for Capricor.<stembedurl>https://stocktwits.com/MrMarB/message/618459744</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 33% this year but has more than doubled its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/uniswap-uni-fair-gas/chlxZJTRRPA">Uniswap Makes Fees Someone Else’s Problem</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

SPDR Series Trust - SPDR Biotech ETF

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$96.77
Prev Close	$97.30
Open	$97.09
Dividend Yield	N/A
50-Day Moving Average	$90.02
Beta	N/A
Avg. Volume	8.48M
PE Ratio	N/A

52-Week High	$105.47
52-Week Low	$66.66
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XBI News

XBI SPDR S&P Biotech ETF